CN102905718A - 纯化多肽的方法 - Google Patents

纯化多肽的方法 Download PDF

Info

Publication number
CN102905718A
CN102905718A CN2011800254040A CN201180025404A CN102905718A CN 102905718 A CN102905718 A CN 102905718A CN 2011800254040 A CN2011800254040 A CN 2011800254040A CN 201180025404 A CN201180025404 A CN 201180025404A CN 102905718 A CN102905718 A CN 102905718A
Authority
CN
China
Prior art keywords
antibody
polypeptide
cation exchange
antibodies
poros
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800254040A
Other languages
English (en)
Chinese (zh)
Inventor
H·F·刘
B·D·凯利
D·E·麦尔斯
B·麦库伊
K·M·佩蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45004368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102905718(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201710269454.2A priority Critical patent/CN107365346A/zh
Publication of CN102905718A publication Critical patent/CN102905718A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2011800254040A 2010-05-25 2011-05-25 纯化多肽的方法 Pending CN102905718A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710269454.2A CN107365346A (zh) 2010-05-25 2011-05-25 纯化多肽的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34814310P 2010-05-25 2010-05-25
US61/348,143 2010-05-25
PCT/US2011/037977 WO2011150110A1 (en) 2010-05-25 2011-05-25 Methods of purifying polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710269454.2A Division CN107365346A (zh) 2010-05-25 2011-05-25 纯化多肽的方法

Publications (1)

Publication Number Publication Date
CN102905718A true CN102905718A (zh) 2013-01-30

Family

ID=45004368

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2011800254040A Pending CN102905718A (zh) 2010-05-25 2011-05-25 纯化多肽的方法
CN201710269454.2A Pending CN107365346A (zh) 2010-05-25 2011-05-25 纯化多肽的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710269454.2A Pending CN107365346A (zh) 2010-05-25 2011-05-25 纯化多肽的方法

Country Status (21)

Country Link
US (5) US20130079272A1 (enExample)
EP (3) EP4492053A3 (enExample)
JP (3) JP5934190B2 (enExample)
KR (1) KR101976853B1 (enExample)
CN (2) CN102905718A (enExample)
AU (1) AU2011258254B2 (enExample)
CA (2) CA2799915C (enExample)
ES (2) ES2991883T3 (enExample)
HK (1) HK1246328A1 (enExample)
HR (2) HRP20241463T1 (enExample)
HU (1) HUE068857T2 (enExample)
IL (2) IL223029A0 (enExample)
MX (2) MX370828B (enExample)
MY (1) MY161534A (enExample)
NZ (1) NZ603648A (enExample)
PL (2) PL3299380T3 (enExample)
RU (1) RU2594163C2 (enExample)
SG (2) SG10201710439UA (enExample)
SI (1) SI2575847T2 (enExample)
WO (1) WO2011150110A1 (enExample)
ZA (1) ZA201208673B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104236983A (zh) * 2013-06-14 2014-12-24 中国科学院大连化学物理研究所 溶液样品中含长烷基链的离子液体的去除方法
CN105848746A (zh) * 2013-09-05 2016-08-10 豪夫迈·罗氏有限公司 用于层析重复利用的方法
CN109765307A (zh) * 2018-12-24 2019-05-17 山东省科学院海洋仪器仪表研究所 一种水体中六氯环己烷的测量方法
CN111366547A (zh) * 2018-12-26 2020-07-03 贵州中烟工业有限责任公司 一种用连续流动法测定烟草或烟草制品中α-氨基氮的检测方法

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
ES2767135T3 (es) * 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
US10364268B2 (en) * 2011-12-22 2019-07-30 Genentech, Inc. Ion exchange membrane chromatography
CN102911250B (zh) * 2012-09-29 2014-04-16 浙江海正药业股份有限公司 酸性重组蛋白药物的纯化方法
CN103880947B (zh) * 2012-12-21 2016-01-13 武汉禾元生物科技股份有限公司 一种分离纯化高纯度重组人血清白蛋白的层析方法
WO2014118685A2 (en) * 2013-01-29 2014-08-07 Dr. Reddy's Laboratories Limited Method of altering the acidic variant content of antibody
WO2014143616A1 (en) 2013-03-14 2014-09-18 Qiagen Sciences Llc Assessing dna quality using real-time pcr and ct values
EP3683232A1 (en) 2013-09-13 2020-07-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
JP6526025B2 (ja) 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
US10214747B2 (en) 2014-01-09 2019-02-26 Kentucky Bioprocessing, Inc. Method of purifying monoclonal antibodies
SI3116891T1 (sl) 2014-03-10 2020-07-31 Richter Gedeon Nyrt. Čiščenje imunoglobulina z uporabo predčistilnih stopenj
WO2015177751A1 (en) * 2014-05-23 2015-11-26 Instituto Massone S.A. A process for obtaining hmg-up (human menopausal gonadotropin with ultra-purity grade) and a composition free of contaminants
EP3145951A1 (en) * 2014-06-24 2017-03-29 InSight Biopharmaceuticals Ltd. Methods of purifying antibodies
GB201411802D0 (en) 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
US10696735B2 (en) * 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
TWI798179B (zh) 2016-06-17 2023-04-11 美商建南德克公司 多特異性抗體之純化
JP7286536B2 (ja) 2016-08-15 2023-06-05 ジェネンテック， インコーポレイテッド 非イオン性サーファクタント及びポリペプチドを含む組成物中の非イオン性サーファクタントを定量するためのクロマトグラフィー法
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
US20220002688A1 (en) * 2018-12-20 2022-01-06 Armagen, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
SG11202107192VA (en) 2019-01-23 2021-07-29 Daiichi Sankyo Co Ltd Methods for purifying antibodies comprising of a process by using activated carbon materials
CN114981286B (zh) 2019-05-03 2026-02-13 豪夫迈·罗氏有限公司 降低从纯化平台获得的组合物中酶水解活性速率的方法
AR119264A1 (es) * 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
CN114599971A (zh) * 2019-10-14 2022-06-07 皮尔斯生物科技有限公司 肽纯化配制物和方法
EP4090666A1 (en) 2020-01-15 2022-11-23 F. Hoffmann-La Roche AG Methods to decrease impurities from recombinant protein manufacturing processes
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
CA3182940A1 (en) * 2020-05-28 2021-12-02 Kashiv Biosciences, Llc An improved process of storing and preparing the protein formulation
WO2022015934A2 (en) * 2020-07-15 2022-01-20 The Johns Hopkins Universtiy Comprehensive analysis of anti-allergen antibodies using phage display
AU2021371309A1 (en) * 2020-10-30 2023-05-18 Genentech, Inc. Purification platforms for obtaining pharmaceutical compositions having a reduced hydrolytic enzyme activity rate
CN112852876B (zh) * 2021-03-04 2022-11-29 西南大学 一种表达人表皮生长因子的家蚕丝腺重组表达载体及其制备方法和应用
MX2023011371A (es) 2021-03-31 2023-10-06 Hoffmann La Roche Purificacion de anticuerpos mediante cromatografia de modo mezclado.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114836A (zh) * 1993-09-21 1996-01-10 赫姆索尔公司 置换色谱方法及纯化的血红蛋白产物
CN1496993A (zh) * 2002-05-15 2004-05-19 ������ҩ�����������ι�˾ 白蛋白纯化
US20090050566A1 (en) * 2007-08-14 2009-02-26 Mikhail Kozlov Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
KR0154872B1 (ko) 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (de) 1992-02-11 2003-07-15 Cell Genesys Inc Erzielen von homozygotem durch zielgerichtete genetische ereignisse
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5545328A (en) * 1993-09-21 1996-08-13 Hemosol Inc. Purification of hemoglobin by displacement chromatography
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
CA2242931A1 (en) * 1996-01-31 1997-08-07 David Francis Elgar Production of an immunoglobulin enriched fraction from whey protein solutions
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
BRPI9910332B8 (pt) * 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
EP1753455A2 (en) 2004-06-04 2007-02-21 Genentech, Inc. Method for treating multiple sclerosis
WO2006031370A2 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
BRPI0518216C8 (pt) † 2004-10-21 2017-03-21 Ge Healthcare Bio Sciences Ab ligante de cromatografia, métodos de preparação de uma matriz de separação, e de separação de um ou mais anticorpos de um ou mais outros compostos em uma amostra líquida, matriz de separação, e, coluna de cromatografia descartável.
DK1869065T3 (da) † 2005-03-11 2020-06-08 Wyeth Llc Fremgangsmåde til kromatografi med svag opdeling
US8129508B2 (en) * 2005-04-11 2012-03-06 Medarex, Inc. Protein purification using HCIC and ion exchange chromatography
US8153009B2 (en) 2005-04-22 2012-04-10 Waters Technologies Corporation Apparatus and methods for mass-spectrometric directed purification of biopolymers
US7691980B2 (en) * 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
JP5361738B2 (ja) 2007-01-22 2013-12-04 ジェネンテック， インコーポレイテッド 多価電解質沈殿物及びタンパク質の精製
MX2009012786A (es) 2007-06-01 2009-12-10 Hoffmann La Roche Purificacion de inmunoglobulina.
CN105315323A (zh) * 2007-10-30 2016-02-10 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
JP5999899B2 (ja) † 2008-04-08 2016-09-28 バイオ−ラッド ラボラトリーズ インコーポレーティッド 抗体のクロマトグラフィー精製法
EP2281000A2 (en) 2008-05-15 2011-02-09 Novo Nordisk A/S Antibody purification process
ES2978373T3 (es) 2008-08-14 2024-09-11 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
EP2360183B1 (en) 2008-12-19 2016-07-27 Takeda Pharmaceutical Company Limited Antibody purification method by mixed mode chromatography utilizing an arginine-containing loading solution
RU2011140486A (ru) * 2009-03-06 2013-04-20 МЕДИММЬЮН, ЭлЭлСи Композиции, содержащие гуманизированные антитела к cd19
ES2817802T3 (es) 2009-08-07 2021-04-08 Emd Millipore Corp Métodos para purificar una proteína objetivo de una o más impurezas en una muestra
WO2011035282A1 (en) 2009-09-21 2011-03-24 Ge Healthcare Bio-Sciences Ab Dual capture separation
WO2011037983A1 (en) * 2009-09-23 2011-03-31 Medarex, Inc. Cation exchange chromatography
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
AU2011329053A1 (en) 2010-11-15 2013-06-06 Biogen Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1114836A (zh) * 1993-09-21 1996-01-10 赫姆索尔公司 置换色谱方法及纯化的血红蛋白产物
CN1496993A (zh) * 2002-05-15 2004-05-19 ������ҩ�����������ι�˾ 白蛋白纯化
US20090050566A1 (en) * 2007-08-14 2009-02-26 Mikhail Kozlov Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOPAL等: "《Rituximab blocks binding of radiolabeled anti-CD20 antibodies(Ab)but not radiolabeled anti-CD45Ab》", 《BLOOD》, vol. 112, no. 3, 31 December 2008 (2008-12-31), pages 830 - 5 *
HAHN等: "《A public idiotypic determinant is present on sponataneous cationic IgG antibodies to DNA from mice of unrelated lupus-prone strains》", 《J IMMUNOL》, vol. 133, no. 6, 31 December 1984 (1984-12-31), pages 3015 - 9 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104236983A (zh) * 2013-06-14 2014-12-24 中国科学院大连化学物理研究所 溶液样品中含长烷基链的离子液体的去除方法
CN105848746A (zh) * 2013-09-05 2016-08-10 豪夫迈·罗氏有限公司 用于层析重复利用的方法
CN105848746B (zh) * 2013-09-05 2019-07-09 豪夫迈·罗氏有限公司 用于层析重复利用的方法
CN109765307A (zh) * 2018-12-24 2019-05-17 山东省科学院海洋仪器仪表研究所 一种水体中六氯环己烷的测量方法
CN111366547A (zh) * 2018-12-26 2020-07-03 贵州中烟工业有限责任公司 一种用连续流动法测定烟草或烟草制品中α-氨基氮的检测方法

Also Published As

Publication number Publication date
ES2637613T3 (es) 2017-10-13
MX344248B (es) 2016-12-09
US20130079272A1 (en) 2013-03-28
EP3299380C0 (en) 2024-08-28
EP2575847B2 (en) 2022-04-27
JP5934190B2 (ja) 2016-06-15
HUE068857T2 (hu) 2025-02-28
EP4492053A3 (en) 2025-03-19
AU2011258254B2 (en) 2016-01-07
HRP20171095T1 (hr) 2017-10-06
HRP20241463T1 (hr) 2025-01-03
SG10201710439UA (en) 2018-01-30
US20250034204A1 (en) 2025-01-30
EP4492053A2 (en) 2025-01-15
US20190300566A1 (en) 2019-10-03
EP2575847B1 (en) 2017-06-14
JP2018087192A (ja) 2018-06-07
ZA201208673B (en) 2016-02-24
IL223029A0 (en) 2013-02-03
HRP20171095T4 (hr) 2022-07-22
US20200399307A1 (en) 2020-12-24
PL2575847T5 (pl) 2022-07-18
EP2575847A1 (en) 2013-04-10
ES2991883T3 (es) 2024-12-05
PL2575847T3 (pl) 2017-10-31
SI2575847T1 (sl) 2017-09-29
IL261147A (en) 2018-10-31
SI2575847T2 (sl) 2022-08-31
CN107365346A (zh) 2017-11-21
AU2011258254A1 (en) 2013-01-10
MX2012013575A (es) 2013-03-21
US20220064209A1 (en) 2022-03-03
CA2799915A1 (en) 2011-12-01
JP2016190851A (ja) 2016-11-10
JP6272941B2 (ja) 2018-01-31
WO2011150110A1 (en) 2011-12-01
CA2799915C (en) 2023-09-26
PL3299380T3 (pl) 2024-12-16
SG185737A1 (en) 2013-01-30
NZ603648A (en) 2014-12-24
CA3209878A1 (en) 2011-12-01
EP3299380B1 (en) 2024-08-28
JP2013530156A (ja) 2013-07-25
RU2012156271A (ru) 2014-06-27
EP2575847A4 (en) 2014-10-08
MY161534A (en) 2017-04-28
KR20130086544A (ko) 2013-08-02
US12152054B2 (en) 2024-11-26
ES2637613T5 (es) 2022-07-20
KR101976853B1 (ko) 2019-05-09
RU2594163C2 (ru) 2016-08-10
EP3299380A1 (en) 2018-03-28
BR112012029904A2 (pt) 2017-08-08
HK1246328A1 (zh) 2018-09-07
MX370828B (es) 2020-01-08

Similar Documents

Publication Publication Date Title
US12152054B2 (en) Methods of purifying polypeptides
JP6979442B2 (ja) オーバーロード／溶出クロマトグラフィー
SG178226A1 (en) Concentrated polypeptide formulations with reduced viscosity
KR20220017436A (ko) 과부하 크로마토그래피 컬럼의 재생 방법
HK1181326A (en) Methods of purifying polypeptides
HK1240254B (zh) 超载和洗脱层析
BR112012029904B1 (pt) Métodos de purificação de anticorpos monoclonais

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1181326

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20130130

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1181326

Country of ref document: HK